Trials / Unknown
UnknownNCT05210582
A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face
An Open Label, Phase II Study to Assess the Changes in Pigmentation and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants in the Treatment of Vitiligo on the Face
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- Clinuvel, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The CUV104 study will assess the efficacy and safety of afamelanotide in patients with vitiligo on the face and body as a monotherapy in repigmentation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afamelanotide | Patients will receive afamelanotide over a three-month period, with an additional three-month follow up. |
Timeline
- Start date
- 2022-10-11
- Primary completion
- 2023-04-01
- Completion
- 2023-08-01
- First posted
- 2022-01-27
- Last updated
- 2023-02-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05210582. Inclusion in this directory is not an endorsement.